The major goal of the Clinical Core is to serve as a resource for the Neuropathology Core and Center Projects #1-4 and facilitate investigations at Johns Hopkins Medical Institutions and collaborating institutions that require subjects with well-characterized Parkinson's disease (PD) and/or postmortem brain tissue.
The Specific Aims are: 1. To conduct longitudinal clinical assessments of individuals with idiopathic PD and age-matched controls. Clinical characterization will involve comprehensive assessments of motor, cognitive, and psychiatric status with longitudinal follow-up until death. These data will facilitate clinicopathological correlations in conjunction with the Neuropathology Core and independent clinical research studies. 2. To maintain and expand a Brain Donation Registry for enrollment of individuals with idiopathic PD and related disorders and age-matched controls who are willing to donate their brain for research purposes after death, thereby providing material for the Neuropathology Core, studies requiring human brain tissue in Projects #1-4, and studies on clinicopathological correlations. 3. To provide the fundamental infrastructure for clinical research on PD that facilitates independently funded clinical investigations of PD at JHMI and collaborating institutions. 4. To train physician-scientists in the clinical assessment and management of patients with PD and related disorders and in the performance of clinical research on PD. Characterization of both motor and non-motor features of PD, their relationships, and their progression over time has implications for identifying clinicopathological correlations and pathophysiological processes that contribute to different etiologies, therapeutic response, and prognosis. Brain tissue from patients with well-characterized clinical features is essential to research on underlying disease mechanisms in PD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS038377-10
Application #
7690704
Study Section
Special Emphasis Panel (ZNS1)
Project Start
Project End
Budget Start
2008-09-01
Budget End
2009-08-31
Support Year
10
Fiscal Year
2008
Total Cost
$257,562
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Hinkle, Jared T; Perepezko, Kate; Mills, Kelly A et al. (2018) Dopamine transporter availability reflects gastrointestinal dysautonomia in early Parkinson disease. Parkinsonism Relat Disord 55:8-14
Kim, Donghoon; Hwang, Heehong; Choi, Seulah et al. (2018) D409H GBA1 mutation accelerates the progression of pathology in A53T ?-synuclein transgenic mouse model. Acta Neuropathol Commun 6:32
Kim, Sangjune; Yun, Seung Pil; Lee, Saebom et al. (2018) GBA1 deficiency negatively affects physiological ?-synuclein tetramers and related multimers. Proc Natl Acad Sci U S A 115:798-803
Kim, Donghoon; Yoo, Je Min; Hwang, Heehong et al. (2018) Graphene quantum dots prevent ?-synucleinopathy in Parkinson's disease. Nat Nanotechnol :
Hinkle, Jared T; Perepezko, Kate; Mari, Zoltan et al. (2018) Perceived Treatment Status of Fluctuations in Parkinson Disease Impacts Suicidality. Am J Geriatr Psychiatry 26:700-710
Kaji, Seiji; Maki, Takakuni; Kinoshita, Hisanori et al. (2018) Pathological Endogenous ?-Synuclein Accumulation in Oligodendrocyte Precursor Cells Potentially Induces Inclusions in Multiple System Atrophy. Stem Cell Reports 10:356-365
Yun, Seung Pil; Kim, Donghoon; Kim, Sangjune et al. (2018) ?-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. Mol Neurodegener 13:1
Hinkle, Jared T; Perepezko, Kate; Rosenthal, Liana S et al. (2018) Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. Parkinsonism Relat Disord 47:50-56
Berger, Nathan A; Besson, Valerie C; Boulares, A Hamid et al. (2018) Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. Br J Pharmacol 175:192-222
Wu, Xinyan; Zahari, Muhammad Saddiq; Renuse, Santosh et al. (2018) Quantitative phosphoproteomic analysis reveals reciprocal activation of receptor tyrosine kinases between cancer epithelial cells and stromal fibroblasts. Clin Proteomics 15:21

Showing the most recent 10 out of 250 publications